{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT03554083","nct_id":"NCT03554083","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03554083. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive vemurafenib PO BID on days 1-28 and cobimetinib PO QD on days 1-21. Patients also receive atezolizumab intravenously (IV) over 30-60 minutes on days 1 and 15 of cycles 2 and 3. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.\n\nWithin 2-4 weeks after treatment, patients undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.","label":"Arm A - CLOSED (vemurafenib, cobimetinib, atezolizumab)","type":"EXPERIMENTAL"},{"description":"Patients receive cobimetinib as in Arm A and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Within 2-4 weeks after treatment, patients undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.","label":"Arm B - CLOSED (cobimetinib, atezolizumab)","type":"EXPERIMENTAL"},{"description":"Patients with BRAF wild-type or BRAF mutant melanoma receive atezolizumab IV over 30-60 minutes and tiragolumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.","label":"Arm C (atezolizumab, tiragolumab)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-04-30","type":"ACTUAL"},"conditions":["Clinical Stage III Cutaneous Melanoma AJCC v8","Pathologic Stage III Cutaneous Melanoma AJCC v8","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8"],"enrollment":{"count":64,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","otherNames":["MPDL 3280A","MPDL 328OA","MPDL-3280A","MPDL3280A","MPDL328OA","RG7446","RO5541267","Tecentriq"],"type":"DRUG"},{"name":"Cobimetinib","otherNames":["Cotellic","GDC-0973","MEK Inhibitor GDC-0973","XL518"],"type":"DRUG"},{"name":"Tiragolumab","otherNames":["MTIG7192A","RG6058"],"type":"BIOLOGICAL"},{"name":"Vemurafenib","otherNames":["BRAF (V600E) kinase inhibitor RO5185426","BRAF(V600E) Kinase Inhibitor RO5185426","PLX-4032","PLX4032","RG 7204","RG7204","RO 5185426","Zelboraf"],"type":"DRUG"}],"last_update":"2026-05-04","lead_sponsor":"Mayo Clinic","official_title":"Neoadjuvant Therapy for Patients With High Risk Stage III Melanoma: A Pilot Clinical Trial","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-04-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Pathologic Complete Response Rate (pCR)","timeFrame":"12 weeks"},{"measure":"Median Recurrence-free (RFS) Rate (Adjuvant Phase)","timeFrame":"3 years"}],"references":[{"citation":"Hieken TJ, Nelson GD, Flotte TJ, Grewal EP, Chen J, McWilliams RR, Kottschade LA, Yang L, Domingo-Musibay E, Dronca RS, Yan Y, Markovic SN, Dimou A, Montane HN, Erskine CL, Piltin MA, Price DL, Khariwala SS, Hui J, Strand CA, Harrington SM, Suman VJ, Dong H, Block MS. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial. Nat Commun. 2024 Feb 16;15(1):1430. doi: 10.1038/s41467-024-45798-8.","pmid":"38365756","type":"RESULT"},{"citation":"Block MS, Nelson GD, Chen J, Johnson S, Yang L, Flotte TJ, Grewal EP, McWilliams RR, Kottschade LA, Domingo-Musibay E, Markovic SN, Dimou A, Montane HN, Piltin MA, Price DL, Khariwala SS, Hui JYC, Erskine CL, Strand CA, Zahrieh D, Dong H, Hieken TJ. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial. J Immunother Cancer. 2025 Apr 15;13(4):e011706. doi: 10.1136/jitc-2025-011706.","pmid":"40234093","type":"RESULT"},{"citation":"Hieken TJ, Price DL, Piltin MA, Turner HJ, Block MS. Surgeon Assessment of the Technical Impact of Neoadjuvant Systemic Therapy on Operable Stage III Melanoma. Ann Surg Oncol. 2022 Feb;29(2):780-786. doi: 10.1245/s10434-021-11112-9. Epub 2021 Nov 25.","pmid":"34825282","type":"RESULT"}],"start_date":{"date":"2018-10-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma","url":"https://clinicaltrials.gov/study/NCT03554083"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03554083"}